Current Location： Home > News Center > Company News

Company News

Oculgen is proud to feature the STAT Study at ARVO 2026 in Denver, Colorado.

Date：2026-05-06 15:35:18 Click：

(低分辨率)3840x1396px OCUL101-002_patient_flyer_v1拆分-01(1).jpg

(低分辨率)3840x1396px OCUL101-002_patient_flyer_v1拆分-02(1).jpg

(低分辨率)3840x1396px OCUL101-002_patient_flyer_v1拆分-03(1).jpg

Oculgen is proud to feature the STAT Study at ARVO 2026 in Denver, Colorado.

The STAT Study is evaluating an investigational drug injection in adults with neovascular age-related macular degeneration (nAMD), with or without geographic atrophy—an advanced form of AMD.

If you're attending ARVO, we invite you to check out our electronic banner to learn more about this ongoing Phase II/III study and our efforts to help navigate a new path forward in AMD treatment.

Previous：【Press Release】Oculgen Announces Initiation of Phase II Clinical Trials for Novel Bispecific Antibod

Next：【Press Release】Oculgen Launches U.S. Phase II/III STAT Study to Advance Treatment for Neovascular Ag